Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up

A clinical trial has found a COVID-19 vaccine in development at a Sinopharm subsidiary to be safe in children aged three to 17 years, according to Chinese state media.

COVID-19 vaccine developers initially focused their clinical trials on adults. Pfizer and Moderna went on to study their candidates in children after showing safety in adults, but even then those trials are only enrolling kids aged 12 years and up. In contrast, China National Biotec Group (CNBG), a subsidiary of Sinopharm, has data on the use of one of its vaccines in kids as young as three years.